---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-006591"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:43:32.514926+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# BMY reports 2021 Abraxane net sales of $1.18B, triggers $4.5M CVR payment

## Summary
- Abraxane net sales for 2021: $1,181,043,283 as recorded in BMY financial statements.
- Net Sales Payment to CVR holders: approximately $4,526,082, payable by March 7, 2022.
- Per CVR payment: approx $0.104592, based on record date March 6, 2022.
- Payment stems from CVRs assumed in 2019 Celgene acquisition under the CVR Agreement.

## SEC filing metadata
- accession: 0001140361-22-006591
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000114036122006591/0001140361-22-006591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000114036122006591/brhc10034437_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-006591
- JSON: https://secwatch.observer/filing/0001140361-22-006591.json
- Plain text: https://secwatch.observer/filing/0001140361-22-006591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.